Angioimmunoblastic T‐cell lymphoma: Novel recurrent mutations and prognostic biomarkers by cell‐free DNA profiling
British Journal of Haematology · 2023
DOI: 10.1111/bjh.19089 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, 2023. Verfasst von Chunlan Zhang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, West China Hospital, Sichuan University, Chengdu, China. Hauptthemen laut MEDLINE: Lymphoma, T-Cell, Cell-Free Nucleic Acids, Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Peripheral. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: Sichuan Science and Technology Department for Key Research and Development Projects, Chengdu Medical Research Project.
Abstract (Originalsprache)
Molecular and clinical stratification of patients with angioimmunoblastic T‐cell lymphoma (AITL) is unsatisfactory, which hinders the development of personalized therapies. This study aimed to identify molecular biomarkers for AITL based on peripheral cell‐free DNA (cfDNA) that could be used to predict prognosis and guide treatment non‐invasively. A customized panel containing 46 genes was used to study pretreatment cfDNA and paired tumour tissues in 64 Chinese AITL patients from three clinical centres, and gene mutations in cfDNA and tumour tissue were assessed for concordance (34 paired samples). Then, the association of gene mutations and prognosis was analysed, and a functional enrichment analysis was performed. The sequencing results showed good consistency between cfDNA samples and paired tissue samples. KDM5A , STAT1 , FANCM , ERBB4 , PIK3R5 and NSD1 were identified as novel recurrent mutations. Mutations in FANCM or combinations of RHOA , KDM5A and FAT1 were associated with poor prognosis. Additionally, functional analysis revealed that RHOA G17 might serve as a predictive biomarker of PD‐1 blockade respondence. Our findings confirmed the role of cfDNA as a liquid biopsy in AITL, and revealed novel molecular determinants that can stratify patients and guide treatment options.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, West China Hospital, Sichuan University, Chengdu, China.
- Precision Medicine Center, Precision Medicine Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Chengdu, China.
ORCID-Profile: Chunlan Zhang, Qinyu Liu, Caigang Xu
Förderung
- Sichuan Science and Technology Department for Key Research and Development Projects
- Chengdu Medical Research Project
Zitieren
APA
Zhang, C., Mou, B., Xu, J., Wang, J., Liu, Q., Yang, Y., Tang, W., Zhong, X., & Xu, C. (2023). Angioimmunoblastic T‐cell lymphoma: Novel recurrent mutations and prognostic biomarkers by cell‐free DNA profiling. British Journal of Haematology. https://doi.org/10.1111/bjh.19089
Vancouver
Zhang C, Mou B, Xu J, Wang J, Liu Q, Yang Y, et al. Angioimmunoblastic T‐cell lymphoma: Novel recurrent mutations and prognostic biomarkers by cell‐free DNA profiling. British Journal of Haematology. 2023. doi:10.1111/bjh.19089
BibTeX
@article{Zhang2023,
author = {Zhang, Chunlan and Mou, Biqin and Xu, Juan and Wang, Jie and Liu, Qinyu and Yang, Yunfan and Tang, Wenjiao and Zhong, Xushu and Xu, Caigang},
title = {Angioimmunoblastic T‐cell lymphoma: Novel recurrent mutations and prognostic biomarkers by cell‐free DNA profiling},
journal = {British Journal of Haematology},
year = {2023},
doi = {10.1111/bjh.19089}
}
EUVIMED